Longitudinal Monitoring of the Growth of Post-Operation Non-Functioning Pituitary Adenomas
Authors:
T. Česák 1; J. Náhlovský 1; T. Hosszú 1; S. Řehák 1; I. Látr 1; S. Němeček 1,2; J. Čáp 3; P. Ryška 4; P. Šuba 1,5; J. Cerman 5,1
Authors‘ workplace:
LF UK v Hradci Králové a FN Hradec Králové: 1Ne urochirurgická klinika, 2Ústav histologi e a embryologi e, 3II. interní klinika, 4Radi odi agnostická klinika, 5Ústav lékařské bi ochemi e
Published in:
Cesk Slov Neurol N 2009; 72/105(2): 115-124
Category:
Original Paper
Overview
Objective:
Non-functioning pituitary adenomas (NFPAs) are regarded as benign, slowly growing tumors. However, aggressive proliferation is not exceptional, especially in younger patients. The aim of the study was to investigate the natural growth patterns of NFPAs and to identify the factors affecting volume progression. As part of the study, nuclear marker Ki-67 was tested as a potentially reliable indicator of postoperative remnant growth potential.
Material:
The study is based on 105 patients operated for NFPAs between 2000 and 2007. The criteria for the inclusion in the study were met by 29 patients (22 men, 7 women).
Results:
The extent of resection was approximately 75 % of the preoperative volume. Tumor consistency was not a limiting factor for the radicality of resection. Factors such as sex, presence of a cyst or invasive growth did not prove to have any significant effect on the level of radicality. Growth curves proved a statistically significant dependence of the rate of growth on the patient’s age. No correlation was found between the rate of growth and the Ki-67 proliferation index. Similarly, no relationship between the rate of growth, tumor invasiveness, sex and the presence of a cyst was observed. Invasiveness was not associated with higher Ki-67 values.
Conclusion:
Based on the results, the following conclusions can be drawn: the rate of NFPAs growth depends on the patient’s age. This fact is useful for treatment strategy as well as postoperative monitoring. The Ki-67 proliferation marker, well-established in human oncology, cannot be considered as a reliable predictive marker of NFPAs growth in our recent study.
Key words:
non‑functi oning pituitary adenomas – postoperative tumo ur remnant/ recurrence – proliferating marker Ki‑67
Sources
1. Nistor R. Pituitary tumo urs. In: Palmer JD (ed). Manu al of ne urosurgery. New York: Churchill Livingstone 1996: 264– 272.
2. Asa SL, Kovacs K. Clinically non‑functi oning human pituitary adenomas. Can J Ne urol Sci 1992; 19(2): 228– 235.
3. Horvath E, Kovacs K. Ultrastructural di agnosis of human pituitary adenomas. Microsc Res Tech 1992; 20(2): 107– 135.
4. Thapar K, Kovacs K, Horvath E, Asa SL. Classificati on and Pathology of Pituitary Tumors. In: Wilkins RH, Rengachary SS (eds). Ne urosurgery. 2nd ed. New York: McGraw- Hill 1996: 1273– 1289.
5. Kovacs K, Horvath E, Vidal S. Classificati on of pituitary adenomas. J Ne uro oncol 2001; 54(2): 121– 127.
6. Němeček S, Němečková J, Cerman J. Patologi e nádorů nervového systému a hypofýzy. In: Náhlovský et al (eds). Ne urochirurgi e. Praha: Galén 2006: 65– 82.
7. Cerman J, Němeček S. Molekulární a genetické aspekty tumorigeneze nervového systému a hypofýzy. In: Náhlovský et al (eds). Ne urochirurgi e. Praha: Galén 2006: 82– 103.
8. Česák T, Náhlovský J, Látr I, Čáp J, Ryška P. Nádorová onemocnění hypofýzy. In: Náhlovský et al (eds). Ne urochirurgi e. Praha: Galén 2006: 155– 176.
9. Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER jr. The long‑term significance of microscopic dural invasi on in 354 pati ents with pituitary adenomas tre ated with transspheno idal surgery. J Ne urosurg 2002; 96(2): 195– 208.
10. Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y,Kobayashi S. Growth pattern and rate in residu al nonfuncti oning pituitary adenomas: correlati on among tumor volume do ubling time, pati ent age, and MIB- 1 index. J Ne urosurg 2003; 98(2): 359– 365.
11. Hardy J. Transspheno idal hypophysectomy. J Ne urosurg 1971; 34(4): 582– 594.
12. Hardy J, Vezina JL. Transspheno idal ne urosurgery of intracrani al ne oplasm. In: Thompson RA, Green JR (eds). Advances in ne urology. New York: Raven Press 1976: 261– 274.
13. Kontoge orgos G, Sambazi otis D, Pi aditis G, Karameris A. Apoptosis in human pituitary adenomas: a morphologic and in situ end‑labeling study. Mod Pathol 1997; 10(9): 921– 926.
14. Náhlovský J, Česák T, Látr I, Čáp J, Žižka J, Krajina A.Komplikace transsfeno idálních operací u našich nemocných – příčiny a řešení. Cesk Slov Ne urol N 2004; 67/ 100(2): 112– 119.
15. Sameš M, Vachata P, Sa ur K, Budíková M. Přímý transnazální miniinvazivní přístup pro mikrochirurgicko u resekci adenomů hypofýzy. Cesk Slov Ne urol N 2005; 68/ 101(5): 338– 343.
16. Masopust V, Netuka D, Hána V, Marek J, Beneš V.Chirurgická léčba hormonálně aktivních adenomů hypofýzy. Cesk Slov Ne urol N 2007; 70/ 103(4): 402– 406.
17. Schwarz TH, Sti eg PE, Anand VK. Endoscopic transspheno idal pituitary surgery with intraoperative magnetic resonance imaging. Ne urosurgery 2006; 58 (Suppl 1): ONS44– ONS51.
18. Lanzi en CF, Larkins M, Mancall A, Loring R, Duchesne a u PM, Rosenblo om SA et al. Crani al postoperative site: MR imaging appe arence. AJNR Am J Ne uroradi ol 1988; 9(1): 27– 34.
19. Rajaraman V, Schulder M. Postoperative MRI appe arence after transspheno idal pituitary tumor resecti on. Surg Ne urol 1999; 52(6): 592– 599.
20. Steiner E, Knosp E, Herold CJ, Kramer J, Stiglba uer R,Staniszewski K et al. Pituitary adenomas: findings of postoperative MR imaging. Radi ology 1992; 185(2): 521– 527.
21. Dina TS, Fe aster SH, Laws ER jr, Davis DO. MR of the pituitary gland postsurgery: Seri al MR studi es following transspheno idal resecti on. AJNR Am J Ne uroradi ol 1993; 14(3): 763– 769.
22. Rodríguez O, Mate os B, de la Pedraja R, Villori a R, Hernando JI, Pastor A et al. Postoperative follow‑up of pituitary adenomas after transspheno idal resecti on: MRI and clinical correlati on. Ne uroradi ology 1996; 38(8): 747– 754.
23. Bradley KM, Adams CB, Potter CP, Wheeler DW, Anslow PJ, Burke CW. An a udit of selected pati ens with non‑functi oning pituitary adenoma tre ated by transspheno idal surgery witho ut irradi ati on. Clin Endocrinol (Oxf) 1994; 41(5): 655– 659.
24. Ciric I, Mikhael M, Stafford T, Lawson L, Garces R. Transspheno idal microsurgery of pituitary macro adenomas with long‑term follow‑up results. J Ne urosurg 1983; 59(3): 395– 401.
25. Comto is R, Be a uregard H, Somma M, Serri O, Aris- Jilwan N, Hardy J. The clinical and endocrine o utcome of trans‑spheno idal microsurgery of nonsecreting pituitary adenomas. Cancer 1991; 68(4): 860– 866.
26. Ebersold MJ, Qu ast LM, Laws ER jr, Scheitha uer B, Randall RV. Long‑term results in transspheno idal removal of nonfuncti oning pituitary adenomas. J Ne urosurg 1986; 64(5): 713– 719.
27. Lillehei KO, Kirschman DL, Kleinschmidt- DeMasters BK, Ridgway EC. Re assessment of the role of radi ati on therapy in the tre atment of endocrine- inactive pituitary macro adenomas. Ne urosurgery 1998; 43(3): 432– 439.
28. Laws ER jr, Pi epgrass DG, Randal RW, Abbo ud CF. Ne urosurgical management of acromegaly. Results in 82 pati ents tre ated between 1972 and 1977. J Ne urosurg 1979; 50(4): 454– 461.
29. Molitch ME, Thormer MO, Wilson C. Management of prolactinomas. J Clin Endocrinol Metab 1997; 82(4): 996– 1000.
30. Randall RV, Scheitha uer BW, Laws ER jr, Abbo ud CF, Ebersold MJ, Kao PC. Pituitary adenomas associ ated with hyperprolactinemi a: a clinical and immunohistochemical study of 97 pati ents operated on transspheno idally. Mayo Clin Proc 1985; 60(11): 753– 762.
31. Hsu DW, Hakim F, Biller BMK, de la Monte S, Zervas NT, Klibanski A et al. Significance of proliferating cell nucle ar antigen index in predicting pituitary adenoma recurrence. J Ne urosurg 1993; 78(5): 753– 761.
32. Thapar K, Kovacs K, Scheitha uer BW, Stefane anu L,Horvath E, Pernicone PJ et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: An analysis using the MIB- 1 antibody. Ne urosurgery 1996; 38(1): 99– 107.
33. Scheitha uer BW, Kovacs KT, Laws ER jr, Randall RV. Pathology of invasive pituitary tumors with speci al reference to functi onal classificati on. J Ne urosurg 1986; 65(6): 733– 744.
34. Selman WR, Laws ER jr, Scheitha uer BW, Carpenter SM. The occurrence of dural invasi on in pituitary adenomas. J Ne urosurg 1986; 64(3): 402– 407.
35. Wilson CB. A decade of pituitary microsurgery. J Ne urosurg 1984; 61(5): 814– 833.
36. Mohr G, Hardy J, Comto is R, Be a uregard H. Surgical management of gi ant pituitary adenomas. Can J Ne urol Sci 1990; 17(1): 62– 66.
37. Knosp E, Steiner E, Kitz K, Matula CH. Pituitary adenomas with invasi on of caverno us sinus space: a magnetic resonance imaging classificati on compared with surgical findings. Ne urosurgery 1993; 33(4): 610– 618.
38. Kitz K, Knosp E, Ko os WT, Korn A. Proliferati on in pituitary adenomas: me asurement by MAb Ki‑67. Acta Ne urochir (Wi en) 1991; 53: 60– 64.
39. Jaffrain‑Re a ML, Di Stefano D, Minniti G, Espozito V,Bultrini A, Ferreti E et al. A critical re appraisal of MIB 1labelling index significance in a large seri es of pituitary tumo urs: secreting versus non‑secreting adenomas. Endocr Relat Cancer 2002; 9(2): 103– 113.
40. Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G. Ki‑67 labelling index and invasiveness among anteri or pituitary adenomas: analysis od 103 cases using MIB- 1 monoclonal antibody. J Clin Pathol 1999; 52(2): 107– 111.
41. Zhao D, Tomono Y, Nose T. Expressi on of P27kip1 and Ki‑67 in pituitary adenomas: an investigati on of marker of adenoma invasiveness. Acta Ne urochir (Wi en) 1999; 141(2): 187– 192.
42. Carboni P jr, Detta A, Hitchcock ER, Postans R. Pituitary adenoma proliferative indices and risk of recurrence. Br J Ne urosurgery 1992; 6(1): 33– 40.
43. Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T. The correlati on of Ki‑67 staining indices with tumo ur do ubling times in regrowing non‑functi oning pituitary adenomas. Acta Ne urochir (Wi en) 1996; 138(12): 1449– 1455.
44. Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R,Vegli a F et al. Proliferating index of nonfuncti oning pituitary adenomas: correlati ons with clinical characteristics and long‑term follow‑up results. Ne urosurgery 2000; 47(6): 1313– 1319.
45. Mizo ue T, Kawamoto H, Arita K, Kurisu K, Tominaga A, Uozumi T. MIB 1 immunopositivity is associ ated with rapid regrowth of pituitary adenomas. Acta Ne urochir (Wi en) 1997; 139(5): 426– 432.
46. Nagashima T, Murovic JA, Hoshino T, Wilson CB, DeArmond SJ. The proliferative potenti al of human pituitary tumors in situ. J Ne urosurg 1986; 64(4): 588– 593.
47. Yonezawa K, Tamaki N, Kokunai T. Clinical fe atures and growth fracti ons of pituitary adenomas. Surg Ne urol 1997; 48(5): 494– 500.
48. Atkin SL, Green LV, Hipkin LJ, Landolt AM, Foy PM, Jeffreys RV et al. A comparison of proliferati on indices in human pituitary adenomas using formalin‑fixed tissue and in vitro cell culture. J Ne urosurg 1997; 87(1): 85– 88.
49. Mastronardi L, Guiducci A, Puzzilli F, Maira G. Anteri or pituitary adenomas in pati ent aged more than 65 ye ars: analysis of growth fracti on (using MIB 1 monoclonal antibody) and of clinical fe atures in comparison to yo unger pati ens. Clin Ne urol Ne urosurg 2002; 104(1): 44– 48.
50. Schreiber S, Saeger W, Lüdecke DK. Proliferati on markers in different types of clinically non‑secreting pituitary adenomas. Pituitary 1999; 1(3– 4): 213– 220.
51. Vidal S, Kovacs K, Horvath E, Rotondo F, Kuroki T, Lloyd RV et al. Topo isomerase II alfa expressi on in pituitary adenomas and carcinomas: relati onship to tumor behavi or. Mod Pathol 2002; 15(11): 1205– 1212.
52. Honegger J, Prettin C, Fe uerhake F, Petrick M, Schulte- Mönting J, Reincke M. Expressi on of Ki‑67 antigen in nonfuncti oning pituitary adenomas: correlati on with growth velocity and invasiveness. J Ne urosurg 2003; 99(4): 674– 679.
53. Abe T, Sanno N, Osamura YR, Matsumoto K. Proliferative potenti al in pituitary adenomas: me asurement by monoclonal antibody MIB- 1. Acta Ne urochir (Wi en) 1997; 139(7): 613– 618.
54. Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T. Analysis of the growth rate and caverno us sinus invasi on of pituitary adenomas. Acta Ne urochir (Wi en) 1995; 136(1– 2): 37– 43.
55. Turner HE, Wass JAH. Are markers of proliferati on valu able in the histological assessment of the pituitary tumo urs? Pituitary 1999; 1(3– 4): 147– 151.
56. Cap J, Cerman J, Nemecek S, Mareková M, Hana V,Frysak Z. The influence of tre atment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH- secreting pituitary adenomas. J Clin Ne urosci 2003; 10(4): 444– 448.
57. Wolfsberger S, Kitz K, Wunderer J, Czech T, Boecher- Schwarz HG, Hainfellner JA et al. Multiregi onal sampling reve als a homogeno us distributi on of Ki‑67 proliferati on rate in pituitary adenomas. Acta Ne urochir (Wi en) 2004; 146(12): 1323– 1328.
58. Lath R, Chacko G, Chandy MJ. Determinati on of Ki‑67 labeling index in pituitary adenomas using MIB- 1 monoclonal antibody. Ne urol Indi a 2001; 49(2): 144– 147.
59. Knosp E, Kitz K, Perneczky A. Proliferati on activity in pituitary adenomas: me asurement by monoclonal antibody Ki‑67. Ne urosurgery 1989; 25(6): 927– 930.
60. Vladyka V, Liščák R, Šimonová G, Chytka T, Novotný J jr, Vymazal J et al. Radi ochirurgické léčení adenomů hypofýzy gama nožem: výsledky u so uboru 163 nemocných získané v intervalu 5 let. Čas Lék česk 2000; 139(24): 757– 766.
Labels
Paediatric neurology Neurosurgery NeurologyArticle was published in
Czech and Slovak Neurology and Neurosurgery
2009 Issue 2
Most read in this issue
- Cervical Myelopathy – a Diagnostic Problem
- Neurodegenerative Dementias
- Malignant Peripheral Nerve She ath Tumor – Two Case Reports
- Radi ofrequency Therapy of Lumbar Facet Pain